Volume 7, Number 1—February 2001
Transferable Plasmid-Mediated Resistance to Streptomycin in Clinical Isolate of Yersinia pestis
Highlight and copy the desired format.
|EID||Guiyoule A, Gerbaud G, Buchrieser C, Galimand M, Rahalison L, Chanteau S, et al. Transferable Plasmid-Mediated Resistance to Streptomycin in Clinical Isolate of Yersinia pestis. Emerg Infect Dis. 2001;7(1):43-48. https://dx.doi.org/10.3201/eid0701.700043|
|AMA||Guiyoule A, Gerbaud G, Buchrieser C, et al. Transferable Plasmid-Mediated Resistance to Streptomycin in Clinical Isolate of Yersinia pestis. Emerging Infectious Diseases. 2001;7(1):43-48. doi:10.3201/eid0701.700043.|
|APA||Guiyoule, A., Gerbaud, G., Buchrieser, C., Galimand, M., Rahalison, L., Chanteau, S....Carniel, E. (2001). Transferable Plasmid-Mediated Resistance to Streptomycin in Clinical Isolate of Yersinia pestis. Emerging Infectious Diseases, 7(1), 43-48. https://dx.doi.org/10.3201/eid0701.700043.|
Plasmid-mediated high-level resistance to multiple antibiotics was reported in a clinical isolate of Yersinia pestis in Madagascar in 1997. We describe a second Y. pestis strain with high-level resistance to streptomycin, isolated from a human case of bubonic plague in Madagascar. The resistance determinants were carried by a self-transferable plasmid that could conjugate at high frequencies to other Y. pestis isolates. The plasmid and the host bacterium were different from those previously associated with multiple-drug resistance, indicating that acquisition of resistance plasmids is occurring in this bacterial species. Emergence of resistance to streptomycin in Y. pestis represents a critical public health problem since this antibiotic is used as the first-line treatment against plague in many countries.
Yersinia pestis is the causative agent of plague, a disease transmitted from rodent to rodent by the bites of fleas. Bubonic plague, the most common form of the disease, occurs through rodent-to-human transmission by infected fleas of peridomestic animals (rats, cats) or wild rodents. Pneumonic plague, a less frequent but highly severe form of the disease, is transmitted from human to human by infected droplets spread by a patient with lung infection (1).
Public health measures and effective antibiotic treatments have led to a drastic decrease in plague worldwide. However, the disease is not eradicated. Endemic plague foci persist in Africa, Asia, and North and South America. During the last 15 years (1982 to 1996), 23,904 human plague cases and 2,105 deaths were reported to the World Health Organization by 24 countries (2). The most affected countries are Madagascar and Tanzania in Africa, Vietnam in Asia, and Peru in the Americas. Since the early 1990s, a steadily increasing trend in human plague cases has been reported to the World Health Organization. This trend is partly attributable to epidemics in places where human plague had disappeared for several decades and has led the World Health Organization to categorize plague as a reemerging disease (3). The reasons for plague's reemergence are not clear but may be partly attributable to inadequate surveillance.
Streptomycin, chloramphenicol, and tetracycline, alone or in combination, are the reference drugs to treat plague, whereas tetracycline or sulfonamides are recommended for prophylaxis (4). Classically, Y. pestis isolates are uniformly susceptible to all antibiotics active against gram-negative bacteria (5–7). Recently, high-level resistance to multiple antibiotics, including those recommended for plague prophylaxis and therapy, was observed in a clinical isolate of Y. pestis in Madagascar (8).
We report high-level resistance to streptomycin (the reference antibiotic for plague treatment) in a second strain of Y. pestis isolated in Madagascar. The resistance genes were carried by a plasmid that could conjugate at high frequencies to other Y. pestis isolates.
Patient and Strains
In our study of the second resistant Y. pestis isolate, Y. pestis 16/95, we used the bacterial strains listed in Table 1. The isolate, biotype Orientalis and ribotype Q, was obtained in 1995 in the Ampitana District of Madagascar from the axillary bubo puncture of a 14-year-old boy before antibiotic treatment. No recent history of travel outside the village was noted. Dead rats were found inside his house before the onset of the disease. The patient was treated with twice-daily intramuscular injections of streptomycin (2 g per day for 4 days) and oral trimethoprim-sulfamethoxazole (2 g per day for 10 days) and recovered.
Media and Resistance Studies
Brain-heart infusion broth and agar (Difco Laboratories, Detroit, MI) were used. The MICs of antibiotics were determined on Mueller-Hinton agar (Sanofi Diagnostics Pasteur, Marnes-la-Coquette, France). The cultures were incubated for 18 hours at 37°C for Escherichia coli and for 48 hours at 28°C for Yersinia strains. Aminoglycoside-modifying enzymes were assayed by the phosphocellulose paper-binding technique (13) in supernatants (centrifuged at 100,000 x g) after ultrasonic bacterial disintegration. Mating on filters was performed as described previously (8). Transfer frequencies were expressed as the number of transconjugants per donor colony-forming unit after the mating period. Antibiotic concentrations for selection were 100 mg/L for ampicillin, 50 mg/L for nalidixic acid, 100 mg/L for rifampicin, and 25 mg/L for streptomycin.
Nucleic Acid Techniques
Isolation of plasmid DNA, cleavage of restriction fragments, and purification of DNA fragments from agarose type VII (Sigma Chemical Co., St. Louis, MO) were performed as described elsewhere (14). Pulsed-field gel electrophoresis was performed for 18 hours with a CHEF-DRIII apparatus (Bio-Rad Laboratories, Richmond, CA), by using an electric field of 6 V/cm and an angle of 120°. Initial and final pulse times were 0.1 second and 6 seconds, respectively. Migration of the DNA fragments was performed in 0.5X Tris-Borate-EDTA buffer in a 0.9% agarose gel at 17°C. DNA sequencing reactions were performed with a Taq BigDye Terminator cycle sequencing kit (Applied Biosystems, Foster City, CA) in a Perkin-Elmer 9700 thermocycler. The samples were loaded onto 4% polyacrylamide gels and electrophoresed on a Model ABI PRISM 377 automatic DNA sequencer (Perkin-Elmer). The nucleotide sequence of the strA and strB genes and of flanking regions from pIP1203 has been deposited in the EMBL data bank under accession number AJ249779.
Streptomycin Resistance in Y. pestis 16/95
Disk-agar diffusion tests showed that Y. pestis 16/95 was resistant to streptomycin but remained susceptible to spectinomycin and other antibiotics, including those recommended for plague therapy (chloramphenicol and tetracycline) and prophylaxis (sulfonamides and tetracycline) (4). The MICs of streptomycin and spectinomycin for this strain were 1,024 mg/L and 16 mg/L, respectively. High-level resistance was due to the presence of a streptomycin phosphotransferase activity. No adenylyltransferase activity was found (data not shown).
Transfer of Streptomycin Resistance to Other Bacterial Species
Attempts were made to transfer streptomycin resistance from Y. pestis 16/95 by conjugation to recipient strains (MIC < 8 mg/L) (Table 2). Transfer occurred at high frequencies (3 x 10-1 per donor CFU) to Y. pestis (MIC = 1,024 mg/L) and Y. pseudotuberculosis (MIC = 256 mg/L) and at lower frequencies to E. coli (MIC = 128 mg/L); transfer to Y. enterocolitica was not detected. Retransfer of streptomycin resistance from Y. pestis and Y. pseudotuberculosis transconjugants to Y. pestis and Y. pseudotuberculosis also occurred at high frequencies (3 x 10-2) and was less efficient when E. coli was used as the recipient strain.
Characterization of Plasmid pIP1203
Plasmid DNA was extracted from Y. pestis 6/69 and 16/95 and digested by EcoRV (Figure 1A). The restriction fragments in strain 6/69 correspond to those of the three Y. pestis resident plasmids, pPla, pYV, and pFra (12). Comparison of the restriction profiles of strains 6/69 and 16/95 revealed that the latter contained at least one extra large-size EcoRV fragment corresponding to an additional plasmid, designated pIP1203. Upon transfer to E. coli, the size of pIP1203 was estimated (after single and double digestion with EcoRI and EcoRV) to be approximately 40 kb (Figure 1B).
Plasmid pIP1203 was stable after 100 generations in Y. pestis 16/95 and E. coli K802N (frequency of loss <0.25%). In experiments performed by reciprocal conjugation to assess the incompatibility group, pIP1203 exhibited strong incompatibility with plasmid RP4 (data not shown), which belongs to the IncP group. No incompatibility with prototype plasmids of incompatibility groups Inc FI, FII, I1, I2, N, 6-C, 7-M, 10-B-O, J, T, and W was observed (15).
Characterization of the Streptomycin-Resistance Genes
To clone the streptomycin-resistant determinant, DNA from plasmids pIP1203 and pUC18 was partially digested with Sau3AI and BamHI, respectively, ligated, and introduced into E. coli JM109 (MIC of streptomycin = 2 mg/L). The smallest recombinant plasmid conferring streptomycin resistance, pAT709, contained an 11-kb insert. The resistance determinant was subcloned by introducing a 2.7-kb HincII fragment of the 11-kb insert into pUC18, which generated pAT710. This recombinant plasmid conferred high levels of resistance to the new host (MIC of streptomycin = 512 mg/L) by synthesis of a streptomycin phosphotransferase. Sequence determination of the insert in pAT710 revealed that the base composition of this fragment was 57.5% G+C, much higher than the average G+C content of the Y. pestis genome (46%) (16). Two potentially coding sequences of 801 bp and 834 bp identified in the insert were identical to the strA and strB genes that encode an aminoglycoside 3"-O-phosphotransferase [APH(3")-Ib] and a 6-O-phosphotransferase [APH(6)-Id], respectively (17). The str genes were originally described in the small, nonconjugative, broad-host-range IncQ plasmid RSF1010 (18). They have been subsequently found as part of transposon Tn5393 and related elements in phytopathogenic Erwinia amylovora, Pseudomonas syringae pv. papulans, and Xanthomonas campestris pv. vesicatoria (19,20).
An 81-bp sequence identical to the inverted terminal repeat (IR) of Tn5393 was identified downstream from pIP1203 strA-strB genes. This IR is always present at the same position in the various genetic structures that carry the str genes (Figure 2). Upstream from strA, the sequence was identical to a portion of the tnpR resolvase-repressor gene of Tn5393, Tn5393a, and Tn5393b (20). The identity was interrupted after 105 bp within the 3'-end of tnpR (Figure 2). Like Tn5393a, pIP1203 possessed the TAG motif, which represents a putative insertion target for IS1133 (20).
The tnpR-strA-strB-IR region of pIP1203, which displayed a Tn5393-like organization, was flanked on both sides by sequences highly similar to portions of the broad-host-range IncP plasmid R751 (21). Upstream from the truncated tnpR gene, there was identity with the 3'-end of the incC2 and the 5'-end of the korB genes [positions 3396 to 3820 of plasmid R751, numbering according to GenBank accession number U67194]. Downstream from the IR, identity was found with a portion of plasmid R751 (positions 9796 to 9947, numbering according to GenBank accession number U67194), located in the vicinity of the oriV vegetative origin of replication.
Y. pestis strain 16/95, isolated in Madagascar in 1995 from a human case of bubonic plague, carried the self-transferable plasmid pIP1203 conferring resistance to streptomycin. The strain of Y. pestis 17/95 harboring the multidrug-resistance conjugative plasmid pIP1202 described in 1997 (8) was also isolated in Madagascar from a human case. However, the two strains differ in several aspects: they were isolated in two districts of Madagascar (Ambalavao and Ampitana) that are 120 km (80 miles) apart; strain 17/95 is of the typical ribotype B, whereas strain 16/95 is of the newly described, Madagascar-specific, ribotype Q (22); plasmid pIP1202 carries multiple antibiotic resistance genes, belongs to the Inc6-C group, and is 150 kb in size, whereas pIP1203 carries only the streptomycin resistance determinants, belongs to the IncP group, and is 40 kb in size; and streptomycin resistance is due to adenylylation of the drug in strain 17/95 and to phosphorylation in strain 16/95. Therefore, the two resistant Y. pestis isolated in Madagascar correspond to distinct strains that have acquired different conjugative plasmids.
The streptomycin resistance genes in pIP1203 are part of the tnpR-strA-strB-IR cluster characteristic of the Tn5393 group of transposons. This portion of the element is inserted in R751, a broad-host-range plasmid belonging to the IncP group. The sequences flanking the tnpR-strA-strB-IR region in pIP1203 are separated by approximately 6 kb in the original R751 backbone (21). This organization suggests that insertion of a Tn5393-like element was associated by concomitant (or subsequent) loss of a region involved in the control of plasmid stability. Despite this deletion, pIP1203 appears to be highly stable in both Y. pestis and E. coli.
IncP plasmids are promiscuous; therefore, the original host of pIP1203 remains unknown. However, since this plasmid was extremely stable in Y. pestis 16/95, conferred high-level resistance to streptomycin, and could transfer at remarkably high frequencies to other strains of Y. pestis, it is possible that pIP1203 was acquired a long time ago and is now well adapted to this bacterial species.
It is not known where genetic transfer of the resistance plasmid took place. During its flea-host-flea cycle, Y. pestis may have been in contact with the donor cell, either in its mammalian host (rodent or human) or the insect vector. In mammals, Y. pestis circulates in a usually sterile milieu (lymphatic vessels, spleen, liver, blood, and sometimes lungs). Contact with the bacterial donor and transfer of pIP1203 may have occurred in the bloodstream at the premortem stage of infection, when gut bacteria invade the host. Alternatively, plasmid acquisition may have taken place in the midgut of the flea, a nonsterile environment where Y. pestis is most likely to be in intimate contact with other microorganisms.
From a clinical and public health point of view, this report is of great concern and indicates that surveillance of antibiotic resistance in Y. pestis should become systematic worldwide. Streptomycin, an inexpensive, easy to use, and highly effective drug against Y. pestis, represents the therapy of choice for plague in Madagascar. Spread of plasmids pIP1202 and pIP1203 among strains of Y. pestis would render streptomycin ineffective for plague treatment and could create economic and therapeutic problems in Madagascar and other countries with endemic plague foci.
A. Guiyoule is a research technician. Her research interests are bacterial pathogenesis and antibiotic resistance.
This work was supported in part by a Bristol-Myers Squibb Unrestricted Biomedical Research Grant in Infectious Diseases.
- Pollitzer R. Plague. In: WHO Monograph Series 22 World Health; Geneva: World Health Organization; 1954.
- World Health Organization. Human plague in 1996. Wkly Epidemiol Rec. 1998;73:366–9.
- Schrag SJ, Wiener P. Emerging infectious diseases: what are the relative roles of ecology and evolution? Trends Evol Ecol. 1995;10:319–24.
- Barnes AM, Quan TJ. Plague. In: Gorbach SL, Bartlett JG, Blacklow NR, editors. Infectious diseases. Philadelphia: W. B. Saunders Company; 1992:1285-91.
- Rasoamanana B, Leroy F, Raharimanana C, Chanteau S. Surveillance de la sensibilité aux antibiotiques des souches de Yersinia pestis à Madagascar de 1989 à 1995. Arch Inst Pasteur Madagascar. 1995;62:108–10.
- Frean JA, Arntzen L, Capper T, Bryskier A, Klugman KP. In vitro activities of 14 antibiotics against 100 human isolates of Yersinia pestis from a southern African plague focus. Antimicrob Agents Chemother. 1996;40:2646–7.
- Smith MD, Vinh DX, Hoa NTT, Wain J, Thung D, White NJ. In vitro antimicrobial susceptibilities of strains of Yersinia pestis. Antimicrob Agents Chemother. 1995;39:2153–4.
- Galimand M, Guiyoule A, Gerbaud G, Rasoamanana B, Chanteau S, Carniel E, Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N Engl J Med. 1997;337:677–80.
- Bachman B. Derivations and genotypes of some mutant derivatives of Escherichia coli K-12. In: Neidhardt F, editor. Escherichia coli and Salmonella, cellular and molecular biology, 2nd ed. Washington, DC: ASM Press; 1996:2460-88.
- Yanisch-Perron C, Vieira J, Messing J. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene. 1985;33:103–19.
- Wood WB. Host specificity of DNA produced by Escherichia coli: bacterial mutations affecting the restriction and modification of DNA. J Mol Biol. 1966;16:118–33.
- Ferber DM, Brubaker RR. Plasmids in Yersinia pestis. Infect Immun. 1981;31:839–41.
- Haas MJ, Dowding JE. Aminoglycoside-modifying enzymes. Methods Enzymol. 1975;43:611–28.
- Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1989.
- DNA insertion elements, plasmids, and episomes. In: Bukhari AI, Shapiro JA, Adhya SL, editors. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1977. p. 601-38.
- Bercovier H, Mollaret HH, Alonso JM, Brault J, Fanning GR, Steigerwalt AG, Intra- and interspecies relatedness of Yersinia pestis by DNA hybridization and its relationship to Yersinia pseudotuberculosis. Curr Microbiol. 1980;4:225–9.
- Shaw KJ, Rather PN, Hare RS, Miller GH. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev. 1993;57:138–63.
- Scholz P, Haring V, Wittmann-Liebold B, Ashman K, Bagdasarian M, Scherzinger E. Complete nucleotide sequence and gene organization of the broad-host-range plasmid RSF1010. Gene. 1989;75:271–88.
- Chiou CS, Jones AL. Nucleotide sequence analysis of a transposon (Tn5393) carrying streptomycin resistance genes in Erwinia amylovora and other gram-negative bacteria. J Bacteriol. 1993;175:732–40.
- Sundin GW, Bender CL. Expression of strA-strB streptomycin resistance genes in Pseudomonas syringae and Xanthomonas campestris and characterization of IS6100 in X. campestris. Appl Environ Microbiol. 1995;61:2891–7.
- Thorsted PB, Macartney DP, Akhtar P, Haines AS, Ali N, Davidson P, Complete sequence of the IncP plasmid R751: implications for evolution and organisation of the IncP backbone. J Mol Biol. 1998;282:969–90.
- Guiyoule A, Rasoamanana B, Buchrieser C, Michel P, Chanteau S, Carniel E. Recent emergence of new variants of Yersinia pestis in Madagascar. J Clin Microbiol. 1997;35:2826–33.
- Figure 1. Analysis of plasmid pIP1203. A) Agarose-gel electrophoresis of EcoRV-digested plasmid DNA from representative Yersinia pestis strain 6/69 (1) and from streptomycin-resistant strain 16/95 (2). B) Pulsed-field gel...
- Figure 2. Genetic organization of the strA-strB genes. Schematic representation of the regions of Tn5393 and derivatives and of plasmids RSF1010, and pIP1203 carrying the strA and strB genes. IR, inverted...
- Table 1. Bacterial strain used in study of resistant Yersinia pestis isolate 16/95
- Table 2. Conjugative transfer of pIP1203
Please use the form below to submit correspondence to the authors or contact them at the following address:
Elisabeth Carniel, Laboratoire des Yersinia, Institut Pasteur, 28 rue du Dr. Roux, 75724 Paris Cedex 15, France; fax: 33-1-40-61-30-01; carniel .
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: March 16, 2011
- Page last updated: March 16, 2011
- Page last reviewed: March 16, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)